U.S. markets close in 1 hour 33 minutes
  • S&P 500

    4,693.17
    +6.42 (+0.14%)
     
  • Dow 30

    35,682.14
    -37.29 (-0.10%)
     
  • Nasdaq

    15,754.57
    +67.65 (+0.43%)
     
  • Russell 2000

    2,270.72
    +16.93 (+0.75%)
     
  • Crude Oil

    72.55
    +0.50 (+0.69%)
     
  • Gold

    1,786.10
    +1.40 (+0.08%)
     
  • Silver

    22.48
    -0.05 (-0.21%)
     
  • EUR/USD

    1.1349
    +0.0077 (+0.68%)
     
  • 10-Yr Bond

    1.5090
    +0.0290 (+1.96%)
     
  • GBP/USD

    1.3232
    -0.0010 (-0.08%)
     
  • USD/JPY

    113.6340
    +0.0940 (+0.08%)
     
  • BTC-USD

    50,612.14
    -541.20 (-1.06%)
     
  • CMC Crypto 200

    1,319.03
    +13.91 (+1.07%)
     
  • FTSE 100

    7,337.05
    -2.85 (-0.04%)
     
  • Nikkei 225

    28,860.62
    +405.02 (+1.42%)
     

SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Longeveron Inc. (LGVN)

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, November 03, 2021--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors of the class action filed on behalf of all persons and entities that purchased Longeveron Inc. (NASDAQ: LGVN) Class A common stock pursuant to or traceable to the Company's February 12, 2021 initial public offering ("IPO"), or between February 12, 2021 and August 12, 2021. Longeveron is a clinical stage biotechnology company that engages in developing cellular therapies for aging-related and life-threatening conditions. The Company's lead investigational product is Lomecel-B, which is currently in Phase 2b of its trial ("Phase 2b Aging Frailty Trial").

If you purchased shares of Longeveron (LGVN) pursuant to the Company's February 12, 2021 IPO, or between February 12 and August 12, 2021, you have until November 12, 2021, to ask the court to appoint you lead plaintiff for the class. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Longeveron Inc. (LGVN) Materially Misrepresented the Viability of its Lead Product Lomecel-B

According to the complaint, Longeveron conducted its IPO on February 12, 2021, issuing 2.66 million Class A shares at $10.00 per share, for approximate proceeds of $24.7 million. However, defendants negligently prepared the Offering Documents in connection with the IPO. Specifically, defendants failed to disclose that: (i) Lomecel-B was not as effective in treating aging frailty as defendants had led investors to believe; (ii) accordingly, Lomecel-B's clinical and commercial prospects with respect to aging frailty were overstated; and (iii) as a result, the Offering Documents and defendants' public statements during the class period were materially false and misleading.

On August 13, 2021, Longeveron issued two press releases – one announcing topline results of the Phase 2b Againg Frailty Trial and one addressing the Company's financial results for the second quarter of 2021. Both press releases disclosed that Lomecel-B had "not achiev[ed] … statistical significance for the pairwise comparison to placebo" with respect to the primary efficacy endpoint. On this news, Longeveron's stock price fell almost 28%, to close at $3.90 per share on August 13, 2021, representing a 61% total decline from the IPO price.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Longeveron Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005473/en/

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com